FDA Approved: TIVDAK — Supplemental Application (SEAGEN INC.)

View source ↗

Summary

The FDA approved a supplemental application for Tivdak (tisotumab vedotin) from Seagen Inc., representing additional regulatory action on this therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TIVDAK (tisotumab vedotin)

Snippet

SUPPL AP for TIVDAK (TISOTUMAB VEDOTIN)